Business
Final Results
SkinBioTherapeutics plc reported a significant increase in revenue to £4.6 million for the year ended June 30, 2025, up 284% from £1.2 million in the prior year, driven by contributions from AxisBiotix™ direct sales, Dermatonics, and Bio-Tech Solutions, alongside royalty income. The company reduced its adjusted EBITDA loss to £0.4 million from £2.1 million and improved its operating loss by 61% to £1.1 million. Cash and cash equivalents stood at £4.8 million, bolstered by successful fundraising efforts totaling £5.76 million. Key operational developments include the finalization of a commercial agreement with Croda for SkinBiotix® (Zenakine™) and the launch of AxisBiotix™ products in over 180 Superdrug stores. The company anticipates FY26 revenue of £6.2 million and adjusted EBITDA of £0.7 million. Disclaimer*
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n\n\n \nSkinBioTherapeutics plc (\"SkinBioTherapeutics\" or the \"Group\" or the \"Company\")\n \nFull Year Results\nContinued growth and evolution of the Group\n \n5 December 2025 - SkinBioTherapeutics plc (AIM: SBTX), a life science group focused on skin health, reports its full year results for the 12 months ended 30 June 2025.\nOperational highlights\n· SkinBiotix®\no Croda studies completed and commercial agreement finalised\no Zenakine™ (SkinBiotix®) launched to the global cosmetics industry in April 2025 and first tranche of royalty income recognised in total Group revenue\n· AxisBiotix™\no Ongoing direct sales growth and continued strong customer retention\no Development of second AxisBiotix™ line for blemish-prone skin\no Exclusive 2 year commercial agreement signed with Superdrug Stores plc\no Post year end, both AxisBiotix™ lines launched in >180 High Street stores\n· Dermatonics\no Revenue of £2.2m (FY24: 1.0m) with EBITDA of £0.5m (FY24: £0.1m) - sales slightly lower than expectations following timing of stocking and additional costs, however, additional expenditure expected to support improved growth in FY26\no Post year end synergies with Bio-Tech Solutions being realised and expected to continue through FY26\n· Bio-Tech Solutions (BTS)\no Acquired in October 2024, adding manufacture and packaging of health, hygiene and personal care products, and future development platform for topical products\no Nine months of reported revenues of £1.4m and EBITDA of £0.1m - slightly lower than expectations due to timing of orders which occurred post year end\no Post year end plans to enhance BTS site in order to support AxisBiotix™ product offering, and to enable production of different grades of cosmetic and medical products\n· Management changes\no Appointment of Dr Surinder 'Dass' Chahal, formerly a senior Croda VP, as Cosmetic Science / Customer Alliances Advisor to the Board, Simon Hewitson as COO and Emily Bertram as Group Finance Director\no Post year end, Simon Hewitson stepped down as COO for personal reasons and Danielle Bekker is stepping down from the Board but will continue to support as an external adviso...